Oklahoma Attorney General Gentner Drummond lauded a recent decision by the Centers for Medicare and Medicaid Services to approve coverage of Leqembi, a new medication that has been shown to slow the progression of Alzheimer’s disease.
According to a news release last week from the Oklahoma AG’s office, Drummond led a 26-state coalition in April urging CMS to provide coverage for Alzheimer’s treatments approved by the U.S. Food and Drug Administration.
“This decision by CMS is momentous in the fight against Alzheimer’s disease,” Drummond said. “The approved coverage for Medicare recipients will significantly increase availability for a promising medication that represents hope for hundreds of thousands of families coping with the heartbreaking impact of Alzheimer’s.”
Drummond’s full letter sent to the U.S. Department of Health & Human Services and CMS can be read here.
